Alder Biopharmaceuticals, Inc.Company Review & Valuation

ALDR
Nasdaq

About Alder Biopharmaceuticals, Inc.

Alder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine and other serious neurological or inflammatory conditions in the United States, AustShow more ralia, and Ireland. The company's lead pivotal-stage product candidate, Eptinezumab, a monoclonal antibody inhibiting calcitonin gene-related peptide, which is in Phase III pivotal trials for the prevention of migraine. Its product candidate pipeline also includes ALD1910, a preclinical monoclonal antibody that targets pituitary adenylate cyclase-activating polypeptide-38; and Clazakizumab, that has completed two Phase 2b clinical trials designed to block the pro-inflammatory cytokine IL-6. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington. Show less

Industry
Biotechnology
HQ Location
Bothell, Washington

Stock Price

Price data not available for Alder Biopharmaceuticals, Inc..

Performance

Please login or create a free account to view the contents of this section.

Similar Companies

back to top